Wegovy for PCOS: Can Semaglutide Help?

What Is PCOS?

Polycystic ovary syndrome, usually shortened to PCOS, is a common hormonal condition. It can affect periods, ovulation, skin, hair growth and the way the body handles insulin. The condition varies considerably. Some people have irregular periods and signs of higher androgen levels, while others mainly notice metabolic or fertility concerns.

PCOS is not caused by body weight, and people with PCOS can have any body size. Higher weight can, however, make insulin resistance and some PCOS symptoms harder to manage. This is why weight-management treatment may form one part of an individual care plan.

Can Wegovy Help With PCOS?

Wegovy contains semaglutide and is licensed for weight management, not for treating PCOS. The international PCOS guideline says anti-obesity medicines, including semaglutide, can be considered for adults with PCOS and higher weight in line with general population guidance.

If Wegovy helps you lose weight, this may improve metabolic health and may support improvements in some weight-related PCOS concerns. It is not possible to promise that it will regulate periods, reduce unwanted hair growth, improve acne or restore fertility. Evidence for those outcomes is still limited, and Wegovy should not replace appropriate PCOS or fertility care.

You can read more about the medicine, available doses and assessment process on our Wegovy injection page.

Who May Be Eligible for Wegovy?

PCOS does not automatically make someone eligible for Wegovy. Under the UK product licence, adults may be considered if their starting BMI is at least 30, or at least 27 with a weight-related health condition. A prescriber must also decide whether treatment is safe and suitable for the individual.

The assessment should cover your medical history, current medicines, previous weight-management treatment, side-effect risks and pregnancy plans. Our BMI calculator for weight-loss injection eligibility can provide an initial indication, but it cannot replace a clinical assessment.

Evidence for Semaglutide and PCOS

The strongest evidence for Wegovy comes from large weight-management trials in adults with overweight or obesity. These studies were not designed to test Wegovy as a PCOS treatment, so their results should not be presented as PCOS-specific outcomes.

Smaller studies and reviews of GLP-1 medicines in people with PCOS suggest possible benefits for weight and some metabolic markers. The quality and size of this evidence are more limited. The 2023 PCOS guideline therefore supports considering semaglutide for managing higher weight, while calling for effective contraception, gradual dose increases and shared decisions about side effects, long-term treatment and the risk of weight regain after stopping.

What results can you expect?

There is no reliable PCOS-specific month-by-month weight-loss schedule. Results vary with dose tolerance, starting weight, eating patterns, activity, health conditions and how long treatment continues. The wider STEP UP trial reported an average body-weight reduction of 20.7% at 72 weeks with Wegovy 7.2 mg and 17.5% with 2.4 mg, but these figures came from adults with obesity as a whole.

Our Wegovy before and after results page explains the broader trial timeline without suggesting that every patient will follow the average.

Wegovy, Insulin Resistance and Metformin

Insulin resistance is common in PCOS, although it does not affect everyone in the same way. Semaglutide helps regulate appetite and blood glucose, and weight loss can improve metabolic health. That does not mean Wegovy directly corrects every aspect of insulin resistance or androgen excess in PCOS.

Metformin is used in PCOS for different reasons, including metabolic features and cycle management in some patients. Wegovy and metformin can sometimes be prescribed together, but the decision should be made by a clinician who understands why each medicine is being used. Both can cause digestive side effects, so nausea, diarrhoea or reduced food intake should be discussed early.

Periods, Fertility and Pregnancy Planning

Wegovy is not a fertility treatment. Some people with PCOS may ovulate more regularly after losing weight, which means pregnancy can become possible even before periods appear predictable. Use effective contraception if pregnancy is not planned.

Wegovy must not be used during pregnancy. The UK prescribing information says semaglutide should be stopped at least two months before a planned pregnancy. If you become pregnant while using it, stop treatment and contact your prescriber promptly.

Unlike tirzepatide, semaglutide does not carry the same specific instruction to add barrier contraception after starting or increasing the dose. Vomiting or severe diarrhoea can still reduce the reliability of oral contraception, so follow the missed-pill advice for your contraceptive and speak to a pharmacist if you are unsure.

Side Effects and Ongoing Support

Nausea, vomiting, diarrhoea, constipation and abdominal discomfort are among the most common Wegovy side effects. The dose is increased gradually to help the body adjust. Smaller meals, adequate fluid and a balanced eating pattern can help, but persistent symptoms should be reviewed rather than simply endured.

Our pages on managing Wegovy side effects and what to eat while using Wegovy offer practical guidance that can be used alongside advice from your prescriber.

Questions to discuss with your prescriber

• Am I eligible for Wegovy under the licensed weight-management criteria?
• Why am I taking metformin or another PCOS medicine, and should it continue?
• Could treatment affect my contraception or pregnancy plans?
• How will we monitor side effects, nutrition and progress?
• What support is available if I later stop treatment?